Total Payments
$555,573
2024 Payments
$58,660
Companies
21
Transactions
517
Medicare Patients
602
Medicare Billing
$66,894
Payment Breakdown by Category
Other$391,812 (70.5%)
Consulting$74,440 (13.4%)
Research$43,688 (7.9%)
Travel$33,728 (6.1%)
Food & Beverage$11,876 (2.1%)
Education$29.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $337,742 | 113 | 60.8% |
| Consulting Fee | $74,440 | 21 | 13.4% |
| Unspecified | $43,688 | 5 | 7.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $38,550 | 10 | 6.9% |
| Travel and Lodging | $33,728 | 160 | 6.1% |
| Honoraria | $12,720 | 10 | 2.3% |
| Food and Beverage | $11,876 | 194 | 2.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,800 | 2 | 0.5% |
| Education | $29.00 | 2 | 0.0% |
Payments by Type
General
$511,886
512 transactions
Research
$43,688
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $202,137 | 202 | $0 (2024) |
| ABBVIE INC. | $194,154 | 172 | $0 (2024) |
| INTERCEPT PHARMACEUTICALS, INC. | $57,802 | 61 | $0 (2022) |
| Madrigal Pharmaceuticals | $30,273 | 27 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $28,038 | 18 | $0 (2020) |
| Allergan Inc. | $11,000 | 1 | $0 (2019) |
| Mallinckrodt Enterprises LLC | $6,935 | 7 | $0 (2019) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $6,136 | 4 | $0 (2023) |
| Sumitomo Pharma America, Inc. | $6,000 | 1 | $0 (2023) |
| Alnylam Pharmaceuticals Inc. | $4,186 | 3 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $58,660 | 60 | Madrigal Pharmaceuticals ($30,273) |
| 2023 | $24,181 | 23 | Gilead Sciences, Inc. ($12,726) |
| 2022 | $34,352 | 40 | Gilead Sciences, Inc. ($20,992) |
| 2021 | $44,228 | 25 | Gilead Sciences, Inc. ($22,962) |
| 2020 | $49,113 | 35 | AbbVie Inc. ($34,129) |
| 2019 | $106,531 | 84 | AbbVie, Inc. ($54,212) |
| 2018 | $97,915 | 97 | AbbVie, Inc. ($37,613) |
| 2017 | $140,593 | 153 | Gilead Sciences Inc ($75,178) |
All Payment Transactions
517 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/20/2024 | ABBVIE INC. | MAVYRET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,125.00 | General |
| Category: VIROLOGY | ||||||
| 12/20/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $121.36 | General |
| Category: LIVER DISEASE | ||||||
| 12/19/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/19/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $115.15 | General |
| Category: LIVER DISEASE | ||||||
| 12/19/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $59.55 | General |
| Category: LIVER DISEASE | ||||||
| 12/17/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/17/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $139.28 | General |
| Category: LIVER DISEASE | ||||||
| 12/17/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $121.36 | General |
| Category: LIVER DISEASE | ||||||
| 12/12/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/12/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $141.76 | General |
| Category: LIVER DISEASE | ||||||
| 12/12/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $45.01 | General |
| Category: LIVER DISEASE | ||||||
| 12/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $6.00 | General |
| 11/21/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $133.21 | General |
| Category: VIROLOGY | ||||||
| 11/20/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/20/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $115.16 | General |
| Category: LIVER DISEASE | ||||||
| 11/20/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $28.14 | General |
| Category: LIVER DISEASE | ||||||
| 11/07/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/07/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: LIVER DISEASE | ||||||
| 11/07/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $107.12 | General |
| Category: LIVER DISEASE | ||||||
| 11/07/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.83 | General |
| 11/06/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/06/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $141.67 | General |
| Category: LIVER DISEASE | ||||||
| 11/06/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $61.09 | General |
| Category: LIVER DISEASE | ||||||
| 10/29/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| M14-423 | AbbVie Inc. | $17,188 | 2 |
| M14-423 | AbbVie, Inc. | $17,125 | 2 |
| An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I) | ABBVIE INC. | $9,375 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 86 | 90 | $140,523 | $11,586 |
| 2022 | 2 | 33 | 33 | $31,851 | $4,002 |
| 2021 | 5 | 149 | 189 | $95,644 | $16,304 |
| 2020 | 11 | 334 | 395 | $211,891 | $35,002 |
Total Patients
602
Total Services
707
Medicare Billing
$66,894
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 31 | 35 | $34,037 | $4,712 | 13.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 11 | 11 | $33,932 | $2,189 | 6.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 18 | 18 | $52,811 | $1,616 | 3.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $11,237 | $1,588 | 14.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 15 | 15 | $8,506 | $1,482 | 17.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 16 | 16 | $17,520 | $2,268 | 12.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 17 | 17 | $14,331 | $1,733 | 12.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 53 | 90 | $27,960 | $5,712 | 20.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 36 | 38 | $20,238 | $4,563 | 22.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 24 | 25 | $12,370 | $2,756 | 22.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 23 | 23 | $9,867 | $2,183 | 22.1% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 13 | 13 | $25,209 | $1,089 | 4.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 74 | 123 | $34,317 | $7,843 | 22.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 46 | 50 | $26,150 | $6,098 | 23.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 38 | 42 | $17,724 | $3,790 | 21.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope | Facility | 2020 | 16 | 16 | $27,280 | $3,721 | 13.6% |
| 45380 | Biopsy of large bowel using an endoscope | Facility | 2020 | 25 | 25 | $20,050 | $2,720 | 13.6% |
| 45378 | Diagnostic examination of large bowel using an endoscope | Facility | 2020 | 17 | 18 | $13,379 | $2,620 | 19.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 24 | 25 | $10,725 | $2,460 | 22.9% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 28 | 28 | $39,284 | $2,263 | 5.8% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 16 | 18 | $9,126 | $1,525 | 16.7% |
| 91200 | Measuring the stiffness in the liver via elastography | Office | 2020 | 36 | 36 | $5,904 | $1,006 | 17.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 14 | 14 | $7,952 | $956.19 | 12.0% |
About Dr. Vinod Rustgi, MD
Dr. Vinod Rustgi, MD is a Gastroenterology healthcare provider based in New Brunswick, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1679589121.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Vinod Rustgi, MD has received a total of $555,573 in payments from pharmaceutical and medical device companies, with $58,660 received in 2024. These payments were reported across 517 transactions from 21 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($337,742).
As a Medicare-enrolled provider, Rustgi has provided services to 602 Medicare beneficiaries, totaling 707 services with total Medicare billing of $66,894. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Gastroenterology
- Location New Brunswick, NJ
- Active Since 08/01/2006
- Last Updated 07/23/2021
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1679589121
Products in Payments
- Epclusa (Drug) $138,664
- Mavyret (Drug) $73,725
- OCALIVA (Drug) $37,999
- REZDIFFRA (Drug) $30,262
- MAVYRET (Drug) $28,227
- OPDIVO (Biological) $27,876
- OCA (Drug) $19,804
- Viekira (Drug) $14,937
- Vemlidy (Drug) $14,082
- XIFAXAN (Drug) $6,136
- Vosevi (Drug) $4,553
- GIVLARRI (Drug) $4,186
- Mulpleta (Drug) $4,102
- EchoTip (Device) $657.18
- TERLIVAZ (Drug) $168.11
- ACQUIRE (Device) $91.15
- Kanuma (Drug) $29.00
- CREON (Drug) $26.40
- Bylvay (Drug) $21.36
- ENDOFLIP (Device) $20.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in New Brunswick
Lea Chen, M.d, M.D
Gastroenterology — Payments: $179,886
Gastroenterology $179,886
Arvind Trindade, Md, MD
Gastroenterology — Payments: $91,569
Gastroenterology $91,569
George Abdelsayed, Md, MD
Gastroenterology — Payments: $43,225
Gastroenterology $43,225
Dr. Avik Sarkar, M.d, M.D
Gastroenterology — Payments: $12,779
Gastroenterology $12,779
Dr. Vishal Jain, Md, MD
Gastroenterology — Payments: $9,858
Gastroenterology $9,858
Dr. Prateek Chapalamadugu, M.d, M.D
Gastroenterology — Payments: $7,913
Gastroenterology $7,913